Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by u2bobon Apr 17, 2018 3:38pm
109 Views
Post# 27899984

RE:REVENUE ESTIMATES 2019

RE:REVENUE ESTIMATES 2019
LannyMcdonald wrote:
April 24th, 2017 - Bangladesh - Eyes For All 

Eyes For All (EFA), through its local office in Dhaka, will be responsible for marketing and execution of the DR scanning. We have been in discussions with multiple parties over the last few months in Bangladesh and are excited about the prospect of rolling out CARA in the country.

I see Eyes for All, following in the foot steps of Al Kanhoor, Pilot should be coming to an end and major contract should be pending, but for now I will keep their estimate low.

Estimate - 2,500 Screenings

July 5th, 2017 - Mar 14th, 2018 - Chaparral Medical Group


We are pleased to sign a three year contract with Diagnos, said Dr Prasad, diabetes specialist, President and Medical Director of Chaparral Medical Group.

Chaparral Medical Group is a 60 physician multi-specialty group serving 23 clinics in Southern California.
Chaparral is introducing AI to enhance the overall value of the annual health examination to Medicare members.

I was only going to give this outfit 2k but with the introduction of Medicare benefits for eye screening this will spike a little. If they can get this kind of set up in clinics around the country, with Medicare fitting the Bill $$$$$

Estimate - 5,000 Screenings


July 17th, 2017 - Mexico - ISSSTE 

 

Based on the execution and results from our 2016 pilot program, ISSSTE now has entrusted DIAGNOS to screen, manage and monitor up to 320,000 patients for the remaining of 2017.

 

Our approach is to monitor ISSSTE’s diabetic population over a 3 year period. Patients screened this year will be back for year 2 and year 3 screenings. This recurring revenue for DIAGNOS ensures the sustainability of our services for the future.


This is black and white . They had a slow start with earth quake in Mexico City. 
Also being the first time they ever rolled out such a big contract. I think they have all the wrinkles ironed out and they should be good to go.

Estimate - 320,000 Screenings


October 17th, 2017 - Cambodia - Garuda Health Services



Garuda Health Services (GHS) first customer will be Royal Phnom Penh Hospital. A new screening service will be offered to their clientele at their annual physical exam. The service is scheduled to be launched in late fall of this year and should cover 22,400 patients under their care.

I see this following in the foot steps of the Saudi Contract, it’s been 5 months and the Saudi contract took 6 months from announcing screening sites to major contract. So we should be hearing soon from Garuda? I will stick with their estimate because the year is just beginning and when they get up and running, it won’t take long to surpass.

Estimate - 22,400 Screenings


Oct 24th, 2017 - North Africa


One-year screening contract in North Africa

During the period covered by the agreement, we estimate that an additional 5,000 patients will be screened in North Africa using our CARA platform.


Working with Big Pharma, no reason not to believe them.

Estimate - 5,000 Screenings 


January 10th, 2018 - Nuevo YO program

 

We needed an accurate technology platform to match our high quality of standards to match our patient-centered Nuevo Yo program and the Diagnos solution filled the requirement that we were looking for ”, states Yiannis Mallis, Vice President & General Manager Mexico.

Pharma-Novo Nordisk


Working with the Biggest Diabetes Pharmaceutical company and for them to release their name in a press release must be worth something? Installing screening sites in local pharmacies? Gee didn’t we discuss this a year ago! 

Estimate - 1,000 Screenings 

February 27th, 2018 - Saudi Arabia - Al Kanhoor

The results were convincing and generated a very positive endorsement from the medical team involved. Kanhoor has agreed to extend its agreement with DIAGNOS for three years. “Our objective is to screen every diabetic patient in the Kingdom with CARA in extending the services to the private health sector, NGO’s and in the public system as well. “Our short term objective is to screen 35,000 in the coming year. We’re in discussions with other health providers with our neighbouring countries in the Middle East so they can also benefit from early detection” said Rashid Al Mugait, president of Kanhoor

Al Kanhoor they have the equipment, Diagnos has the solution, this was a match made in heaven!

I will stick with the 35,000 for now but this has major potential!

Estimate - 35,000 Screenings 

March 7th, 2018 - UAE 
 

So far, DIAGNOS’ healthcare services have been rendered in 16 countries worldwide. During the period covered by the agreement, we estimate that an additional 2,500 patients will be screened in UAE using our CARA platform.


Enough with the pilots UAE, it’s time to put your stones on the table and sign a major contract ! Your Diabetes pandemic is not going away anytime soon.

Estimate - 2,500 Screenings 





So to tally that

Bangladesh.              2,500
USA.                         5,000
Mexico.                 320,000
Cambodia.              22,400
N. Africa.                  5,000
Nuevo YO.                1,000
Saudi Arabia.           35,000
UAE.                          2,500

Total                       393,400  x 15 per Scan = $5,901,000

Brazilian contract looming in the weeds !!
Im sure Andr has a few rabbits in his hat that we don’t know about either!!!
We double that number above if we add Cara Cardio !!
Diagnos is still at the tip of the iceberg 

I emailed Andre Larente CEO of Diagnos yesterday and he happily responded to me saying “ EVERYTHING IS GOING ACCORDING TO PLAN” 

Have a great weekend! 

Lanny





Hey Lanny do you think Andre is having to go head to head with these guys ?

Maybe why UAE is slow in signing a contract ?

I did send him a message about this ...he responded back saying he is aware of it now... and that things are going well...lets hope that means contracts to be signed soon...or something News worthy ...here is why I think UAE are dragging their feet !

I would like to think this NEXT PILOT WITH UAE will show how much futher ahead we are...with Cardio next and grading of scans... plus blockchain in the next version of CARA ...




AI diagnoses eye disease with 96pc accuracy

DUBAI, February 28, 2018

 

Dubai Health Center’s (DHA) artificial intelligence (AI) program has recorded an accuracy of 96 per cent in diagnosing retinal damage, a top official said.

DHA’s Dubai Diabetes Center’s provided the images that were fed into an AI program developed by Artelus, Dubai company focused in AI research in healthcare, said Dr M Hamed Farooqi, director of the Center.

“The more scans are fed to the program the more accurate the diagnosis will be. These positive results will be considered in possibly adopting this program at the center,” he added.

Dr Farooqi explained that along with this high prevalence of diabetes comes a high global prevalence of retinal damage as more than 93 million people are diagnosed with eye damage and 1 in 3 diabetics will develop diabetic retinopathy, according to international statistics.

He highlighted that diabetic retinopathy is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye. At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness.

He said to diagnose diabetic retinopathy regular retinal imaging is required and in some cases optical coherence tomography is also used. This imaging test provides cross-sectional images of the retina that show the thickness of the retina, which will help determine whether fluid has leaked into retinal tissue.

Dr Farooqi said that usually seven pictures of each eye are needed to diagnose retinal damage; this means that doctors need go through thousands of scans to diagnose patients.

Dr Farooqi said adopting AI will allow patients to receive their results faster leading to early detection, which can result in the better management of the condition. He said that AI will also reduce the overall cost of managing the retinal complications.

Meanwhile, Pradeep Walia, co-founder of Artelus LLC said that latest advances in AI would bring primary health screening to those most in need, and raise awareness in the masses. Early detection of Diabetic Retinopathy has shown to prevent blindness. By using AI and Machine Learning, and the use of cutting edge AI algorithms will enable the communities to offer large-scale screening at a fraction of the cost and save doctors a lot time.

DHA displayed its Artificial Intelligence (AI) in diagnosing Eye Disease initiative during its participation in the UAE Innovation Month 2018.

The UAE Innovation Month, which is the largest celebration of its kind that seeks to celebrate the best in ideas on innovation from the government and private sectors as well as from the public.

The second phase of the Dubai Diabetes Survey 2017 revealed that the total prevalence of Diabetes amongst Emiratis in Dubai is 19 per cent, while the total of undiagnosed diabetes cases of Emiratis is 11 percent and the rate of pre-diabetic Emiratis is 18.6 per cent. – TradeArabia News Service



Bullboard Posts